Endogenous retroviruses expressed in human tumours cannot be used as targets for anti-tumour vaccines

Denner, 2010, Endogenous retroviruses, 35

Vergara Bermejo, 2020, Cancer associated endogenous retroviruses: ideal immune targets for adenovirus-based immunotherapy, Int. J. Mol. Sci., 21, E4843, 10.3390/ijms21144843

Thiel, 1987, Role of antibodies to murine leukemia virus p15E transmembrane protein in immunotherapy against AKR leukemia: a model for studies in human acquired immunodeficiency syndrome, Proc. Natl. Acad. Sci. USA, 84, 5893, 10.1073/pnas.84.16.5893

Bronte, 2003, Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase, J. Immunol., 171, 6396, 10.4049/jimmunol.171.12.6396

Takeda, 2000, Anti-tumor immunity against CT26 colon tumor in mice immunized with plasmid DNA encoding beta-galactosidase fused to an envelope protein of endogenous retrovirus, Cell Immunol., 204, 111, 10.1006/cimm.2000.1691

Kraus, 2013, Vaccination directed against the human endogenous retrovirus-K envelope protein inhibits tumor growth in a murine model system, PLoS One, 8, e72756, 10.1371/journal.pone.0072756

Fuchs, 2013, Human endogenous retrovirus K (HML-2) RNA and protein expression is a marker for human embryonic and induced pluripotent stem cells, Retrovirology, 10, 115, 10.1186/1742-4690-10-115

Tacke, 2003, Differences in release and determination of subtype of porcine endogenous retroviruses produced by stimulated normal pig blood cells, Intervirology, 46, 17, 10.1159/000068120

Stoye, 1983, Endogenous retrovirus expression in stimulated murine lymphocytes. Identification of a new locus controlling mitogen induction of a defective virus, J. Exp. Med., 157, 1660, 10.1084/jem.157.5.1660